JPMorgan Healthcare Leaders ETF
Schedule of Portfolio Investments as of July 31, 2024
(Unaudited)
THE “UNAUDITED EXCHANGE-TRADED FUNDS HOLDINGS” LIST (“the List”) IS TO BE USED FOR REPORTING PURPOSES ONLY. IT IS NOT TO BE REPRODUCED FOR USE AS ADVERTISING OR SALES LITERATURE WITH THE GENERAL PUBLIC. The list is submitted for the general information of the shareholders of the Fund. It is not authorized for distribution to prospective investors in the Fund unless preceded or accompanied by a prospectus. The list has been created from the books and records of the Fund. Holdings are available 60 days after the fund’s fiscal quarter, using a trade date accounting convention, by contacting the appropriate service center. The list is subject to change without notice. The list is for informational purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security. |
JPMorgan Asset Management is the marketing name for the asset management business of J.P. Morgan Chase & Co. |
J.P. Morgan Distribution Services, Inc., member FINRA. |
© J.P. Morgan Chase & Co., 2024. |
JPMorgan Healthcare Leaders ETF
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF July 31, 2024 (Unaudited)INVESTMENTS | SHARES | VALUE($) |
Common Stocks — 99.0% | ||
Denmark — 6.6% | ||
Novo Nordisk A/S, Class B | 3,280 | 434,576 |
Zealand Pharma A/S * | 456 | 61,433 |
496,009 | ||
Germany — 0.6% | ||
Sartorius AG (Preference) | 164 | 46,514 |
Japan — 2.1% | ||
Daiichi Sankyo Co. Ltd. | 3,000 | 122,183 |
Kyowa Kirin Co. Ltd. | 1,900 | 40,076 |
162,259 | ||
Netherlands — 1.2% | ||
Argenx SE * | 166 | 83,485 |
Argenx SE * | 8 | 4,090 |
87,575 | ||
Switzerland — 2.8% | ||
Lonza Group AG (Registered) | 178 | 118,532 |
Novartis AG (Registered) | 378 | 42,195 |
Sonova Holding AG (Registered) | 153 | 46,900 |
207,627 | ||
United Kingdom — 4.5% | ||
AstraZeneca plc | 2,156 | 342,526 |
United States — 81.2% | ||
Abbott Laboratories | 395 | 41,846 |
AbbVie, Inc. | 2,028 | 375,829 |
Acadia Healthcare Co., Inc. * | 540 | 35,019 |
Agios Pharmaceuticals, Inc. * | 977 | 45,333 |
Align Technology, Inc. * | 91 | 21,101 |
Alnylam Pharmaceuticals, Inc. * | 134 | 31,820 |
Amgen, Inc. | 236 | 78,463 |
Amicus Therapeutics, Inc. * | 2,404 | 24,785 |
Apellis Pharmaceuticals, Inc. * | 740 | 29,304 |
Arvinas, Inc. * | 809 | 22,256 |
Becton Dickinson & Co. | 526 | 126,798 |
Biogen, Inc. * | 242 | 51,594 |
Biohaven Ltd. * | 550 | 21,631 |
BioMarin Pharmaceutical, Inc. * | 592 | 49,923 |
Blueprint Medicines Corp. * | 408 | 44,186 |
Boston Scientific Corp. * | 2,554 | 188,689 |
Bristol-Myers Squibb Co. | 2,803 | 133,311 |
Cigna Group (The) | 512 | 178,519 |
Danaher Corp. | 1,152 | 319,196 |
Dexcom, Inc. * | 640 | 43,405 |
Eli Lilly & Co. | 814 | 654,676 |
Evolent Health, Inc., Class A * | 1,441 | 33,604 |
Exact Sciences Corp. * | 1,020 | 46,594 |
Halozyme Therapeutics, Inc. * | 953 | 52,663 |
JPMorgan Healthcare Leaders ETF
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF July 31, 2024 (Unaudited) (continued)INVESTMENTS | SHARES | VALUE($) |
Common Stocks — continued | ||
United States — continued | ||
HCA Healthcare, Inc. | 333 | 120,896 |
Humana, Inc. | 196 | 70,876 |
IDEXX Laboratories, Inc. * | 34 | 16,188 |
Inspire Medical Systems, Inc. * | 257 | 36,250 |
Intra-Cellular Therapies, Inc. * | 626 | 49,279 |
Intuitive Surgical, Inc. * | 220 | 97,814 |
IQVIA Holdings, Inc. * | 447 | 110,065 |
iRhythm Technologies, Inc. * | 349 | 30,101 |
Johnson & Johnson | 1,106 | 174,582 |
McKesson Corp. | 303 | 186,957 |
Merck & Co., Inc. | 1,365 | 154,422 |
Natera, Inc. * | 379 | 38,806 |
Neurocrine Biosciences, Inc. * | 436 | 61,725 |
Regeneron Pharmaceuticals, Inc. * | 285 | 307,569 |
REVOLUTION Medicines, Inc. * | 694 | 31,674 |
Roche Holding AG | 789 | 255,446 |
Sanofi SA | 1,424 | 146,804 |
Sarepta Therapeutics, Inc. * | 315 | 44,806 |
Stryker Corp. | 492 | 161,105 |
Thermo Fisher Scientific, Inc. | 589 | 361,257 |
Twist Bioscience Corp. * | 698 | 38,955 |
UnitedHealth Group, Inc. | 1,232 | 709,829 |
Vertex Pharmaceuticals, Inc. * | 376 | 186,391 |
West Pharmaceutical Services, Inc. | 209 | 63,990 |
6,106,332 | ||
Total Common Stocks (Cost $6,299,723) | 7,448,842 | |
Short-Term Investments — 2.1% | ||
Investment Companies — 2.1% | ||
JPMorgan U.S. Government Money Market Fund Class IM Shares, 5.25% (a) (b)(Cost $153,849) | 153,849 | 153,849 |
Total Investments — 101.1% (Cost $6,453,572) | 7,602,691 | |
Liabilities in Excess of Other Assets — (1.1)% | (80,025 ) | |
NET ASSETS — 100.0% | 7,522,666 |
Percentages indicated are based on net assets. |
Abbreviations | |
Preference | A special type of equity investment that shares in the earnings of the company, has limited voting rights, and may have a dividend preference. Preference shares may also have liquidation preference. |
* | Non-income producing security. |
(a) | Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan Investment Management Inc. |
(b) | The rate shown is the current yield as of July 31, 2024. |
JPMorgan Healthcare Leaders ETF
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF July 31, 2024 (Unaudited) (continued)Summary of Investments by Industry, July 31, 2024
The following table represents the portfolio investments of the Fund by industry classifications as a percentage of total investments:
INDUSTRY | PERCENT OF TOTAL INVESTMENTS |
Pharmaceuticals | 33.8 % |
Biotechnology | 22.5 |
Health Care Providers & Services | 17.1 |
Life Sciences Tools & Services | 13.4 |
Health Care Equipment & Supplies | 10.7 |
Health Care Technology | 0.5 |
Short-Term Investments | 2.0 |
JPMorgan Healthcare Leaders ETF
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF July 31, 2024 (Unaudited) (continued)A. Valuation of Investments— Investments are valued in accordance with U.S. generally accepted accounting principles (“GAAP”) and the Fund's valuation policies set forth by, and under the supervision and responsibility of, the Board of Trustees of the Trust (the “Board”), which established the following approach to valuation, as described more fully below: (i) investments for which market quotations are readily available shall be valued at their market value and (ii) all other investments for which market quotations are not readily available shall be valued at their fair value as determined in good faith by the Board.
Under Section 2(a)(41) of the Investment Company Act of 1940, the Board is required to determine fair value for securities that do not have readily available market quotations. Under SEC Rule 2a-5 (Good Faith Determinations of Fair Value), the Board may designate the performance of these fair valuation determinations to a valuation designee. The Board has designated the Adviser as the “Valuation Designee” to perform fair valuation determinations for the Fund on behalf of the Board subject to appropriate oversight by the Board. The Adviser, as Valuation Designee, leverages the J.P. Morgan Asset Management Americas Valuation Committee (“AVC”) to help oversee and carry out the policies for the valuation of investments held in the Fund. The Adviser, as Valuation Designee, remains responsible for the valuation determinations.
This oversight by the AVC includes monitoring the appropriateness of fair values based on results of ongoing valuation oversight including, but not limited to, consideration of macro or security specific events, market events, and pricing vendor and broker due diligence. The Administrator is responsible for discussing and assessing the potential impacts to the fair values on an ongoing basis, and, at least on a quarterly basis, with the AVC and the Board.
Equities and other exchange-traded instruments are valued at the last sale price or official market closing price on the primary exchange on which the instrument is traded before the net asset value (“NAV”) of the Fund is calculated on a valuation date. Certain foreign equity instruments are valued by applying international fair value factors provided by an approved Pricing Service. The factors seek to adjust the local closing price for movements of local markets post-closing, but prior to the time the NAV is calculated.
Investments in open-end investment companies (“Underlying Funds”) are valued at each Underlying Fund’s NAV per share as of the report date.
Valuations reflected in this report are as of the report date. As a result, changes in valuation due to market events and/or issuer-related events after the report date and prior to issuance of the report are not reflected herein.
The various inputs that are used in determining the valuation of the Fund's investments are summarized into the three broad levels listed below.
•
Level 1 — Unadjusted inputs using quoted prices in active markets for identical investments.
•
Level 2 — Other significant observable inputs including, but not limited to, quoted prices for similar investments, inputs other than quoted prices that are observable for investments (such as interest rates, prepayment speeds, credit risk, etc.) or other market corroborated inputs.
•
Level 3 — Significant inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Fund's assumptions in determining the fair value of investments).
A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input, both individually and in the aggregate, that is significant to the fair value measurement. The inputs or methodology used for valuing instruments are not necessarily an indication of the risk associated with investing in those instruments.
The following table represents each valuation input as presented on the Schedule of Portfolio Investments:
Level 1 Quoted prices | Level 2 Other significant observable inputs | Level 3 Significant unobservable inputs | Total | |
Investments in Securities | ||||
Common Stocks | ||||
Denmark | $— | $496,009 | $— | $496,009 |
Germany | — | 46,514 | — | 46,514 |
Japan | — | 162,259 | — | 162,259 |
Netherlands | 83,485 | 4,090 | — | 87,575 |
Switzerland | — | 207,627 | — | 207,627 |
United Kingdom | — | 342,526 | — | 342,526 |
United States | 5,704,082 | 402,250 | — | 6,106,332 |
Total Common Stocks | 5,787,567 | 1,661,275 | — | 7,448,842 |
JPMorgan Healthcare Leaders ETF
SCHEDULE OF PORTFOLIO INVESTMENTS
AS OF July 31, 2024 (Unaudited) (continued)Level 1 Quoted prices | Level 2 Other significant observable inputs | Level 3 Significant unobservable inputs | Total | |
Short-Term Investments | ||||
Investment Companies | $153,849 | $— | $— | $153,849 |
Total Investments in Securities | $5,941,416 | $1,661,275 | $— | $7,602,691 |
B. Investment Transactions with Affiliates— The Fund invested in an Underlying Fund advised by the Adviser. An issuer which is under common control with the Fund may be considered an affiliate. The Fund assumes the issuer listed in the table below to be an affiliated issuer. The Underlying Fund's distributions may be reinvested into such Underlying Fund. Reinvestment amounts are included in the purchases at cost amounts in the table below.
For the period ended July 31, 2024 | |||||||||
Security Description | Value at November 1, 2023(a) | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation/ (Depreciation) | Value at July 31, 2024 | Shares at July 31, 2024 | Dividend Income | Capital Gain Distributions |
JPMorgan U.S. Government Money Market Fund Class IM Shares, 5.25% (b) (c) | $— | $10,049,101 | $9,895,252 | $— | $— | $153,849 | 153,849 | $4,591 | $— |
(a) | Commencement of operations was November 1, 2023. |
(b) | Investment in an affiliated fund, which is registered under the Investment Company Act of 1940, as amended, and is advised by J.P. Morgan Investment Management Inc. |
(c) | The rate shown is the current yield as of July 31, 2024. |